ASCO 2021 Ovarian Cancer

Genetic testing for BRCA1/2 mutations is recommended for all women with ovarian cancer, given the important implications for treatment and prognosis, according to the Caitlin E. Taylor, MD, lead author of a paper presented at...

It has long been identified that Black women with ovarian cancer have worse overall survival when compared to White women, explains Deanna L Huffman, DO, Department of Internal Medicine, Allegheny Health Network, in Pittsburgh....

Effective patient-clinician communication (PCC) is central to the delivery of high-quality care, according to the National Cancer Institute (NCI), and it becomes even more crucial in the cancer setting where patients deal with...

A better understanding of the burden of treatment side effects in patients with gynecological malignancies could help guide symptom interventions and oncologic therapy decision-making, according to Ashley D. Hickman, MD, the...

Adavosertib with or without olaparib shows efficacy in women with PARP inhibitor-resistant ovarian cancer (Abstract #5505) Clinical trial results from the randomized, non-comparative Phase II EFFORT study showed that...

The phase III PAOLA-1/ENGOT-ov25 trial evaluated the addition of maintenance olaparib to bevacizumab in women with advanced ovarian cancer who were in response after first-line platinum-based CTx with bevacizumab. In the Phase...

Clinical trial results from the randomized, non-comparative Phase II EFFORT study showed that adavosertib, a Wee1 inhibitor, was effective in patients with PARP inhibitor-resistant ovarian cancer when given alone and in...

Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with...

Testing for mutations in BRCA1 and BRCA2 is recommended for all women with ovarian cancer, given important implications for treatment and prognosis. Despite this recommendation, studies show that only a small percentage of...

Although ovarian cancer is the third most common Lynch syndrome (LS)-associated cancer in women, there is no established screening strategy to identify LS in this population. It is hypothesized that an adequate family history...

Disparities in the adherence to National Comprehensive Cancer Network (NCCN) guideline-directed treatment and socioeconomic characteristics may be responsible for the differences in ovarian cancer outcomes of ovarian cancer in...

The National Cancer Institute (NCI) Framework for patient-centered communication (PCC) in Cancer Care highlights the potential of PCC to improve health-related quality of life (HRQoL), but to date, few studies have empirically...

The ASCO Annual Meeting enters its second year in a virtual setting June 4-8, 2021, to ensure the safety and health of attendees while delivering groundbreaking science in oncology and timely information on clinical application...